Navigation Links
Data From LigoCyte's Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research

BETHESDA, Md., April 28 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private biopharmaceutical company focused on the development of innovative vaccine products, announced today that results from two Phase I studies of its norovirus virus-like particle (VLP) vaccine candidate were presented today at the 13th Annual Conference on Vaccine Research. Sponsored by the National Foundation of Infectious Diseases, the conference is being held in Bethesda, Maryland, from April 26-28, 2010.

Donald P. Beeman, Chief Executive Officer of LigoCyte, commented, "Each year, nearly 23 million Americans are infected with norovirus, the leading worldwide cause of infectious gastroenteritis, or inflammation of the stomach and intestines marked by acute vomiting and diarrhea. Epidemic outbreaks in hospitals, nursing homes and schools highlight this virus's significant burden, including serious and sometimes life-threatening complications.

"Given the urgency for prevention strategies, we are excited that Phase I data for LigoCyte's novel norovirus vaccine could be shared at NFID's Annual Conference on Vaccine Research."

Data presented during the conference were from two Phase I trials evaluating different dosage levels of the norovirus VLP vaccine candidate. The objective of the double-blind studies was to evaluate the vaccine's safety and immunogenicity in healthy volunteers, ages 18-49. Subjects were randomized to receive two doses of intranasal norovirus VLP vaccine (containing a Norwalk strain) or controls 21 days apart.  The clinical results showed the vaccine to be immunogenic and generally well tolerated in human subjects. Local nasal symptoms, including for example nasal stuffiness, were common and generally brief. No vaccine-related serious adverse events occurred.  

"This is a unique example of a vaccine against an enteric virus that was well tolerated and highly immunogenic when given intranasally. The vaccine activated immune cells with the capacity to migrate to the gastrointestinal tract and produce antibodies that have the potential to prevent infection," said Marcela F. Pasetti, Ph.D., Associate Professor of Pediatrics at the University of Maryland School of Medicine, who presented the data at the Vaccine Research Conference. Dr. Pasetti also is chief of the Applied Immunology Section at the University of Maryland Center for Vaccine Development.

The investigational, nasally delivered, dry powder vaccine is currently being examined in a Phase I/II study designed to assess safety and immunogenicity plus potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo. The company expects to release interim results for this study next quarter. In addition, the company expects to begin a Phase I trial with an intramuscular version of norovirus VLP vaccine before the end of 2010.

About Norovirus Infection

Norovirus infection, well known as the "stomach flu," is the most common cause of acute gastroenteritis, afflicting nearly 23 million Americans annually. Norovirus infection is characterized by the acute onset of nausea, vomiting, abdominal cramps, diarrhea, and occasionally fever. Severe clinical outcomes are associated with at-risk populations, where complications caused by infection can disrupt primary treatment regimens and even lead to death. Noroviruses are highly infective and easily transmitted. Epidemic outbreaks occur in community environments, particularly hospitals, hotels, schools, and nursing homes, resulting in significant risk to immunocompromised individuals and mounting socioeconomic cost to families, the health care system and businesses. Military units are also affected, as outbreaks represent a significant readiness issue for naval vessels and land-based installations.

About LigoCyte's Norovirus Vaccine Candidate

LigoCyte's norovirus vaccine is a needle-free, dry powder formulation based on virus-like particle (VLP) antigens, which are highly purified protein products. By preserving the authentic conformation of the viral capsid, VLPs mimic the antigen presentation of the live virus while lacking the ability to reproduce or cause illness. LigoCyte's vaccine formulation also includes the adjuvant Monophosphoryl Lipid A, provided under license from GlaxoSmithKline (NYSE: GSK), and chitosan (ChiSys®) to enhance nasal delivery, under license from Archimedes Development Ltd. LigoCyte's challenge study will utilize a live Norwalk virus inoculum developed at Baylor College of Medicine with funding from the National Institutes of Health. Additional information about the study can be found at

About the Vaccine Research Conference

The Annual Conference on Vaccine Research provides current, high-quality reports of scientific progress featured in both invited presentations and submitted abstracts. The wide range of topics, covered in both human and veterinary vaccinology, offers a thorough picture of the opportunities, challenges and discoveries associated with vaccine development, production and distribution. The conference is sponsored by the National Foundation for Infectious Diseases (NFID) and held in collaboration with the Center for Biologics Evaluation and Research/Food and Drug Administration, Centers for Disease Control and Prevention, Center for Vaccine Development of the University of Maryland, Fondation Merieux, International Association for Biologicals, International Society for Vaccines, International Vaccine Institute, National Institute for Allergy and Infectious Diseases, The Jenner Society, Sabin Vaccine Institute and United States Department of Agriculture. Founded in 1973, NFID is a non-profit organization dedicated to educating the public and healthcare professionals about the causes, treatment and prevention of infectious diseases.

About LigoCyte

LigoCyte is a private, clinical-stage biotechnology company focused on developing novel vaccines for gastrointestinal and respiratory indications. LigoCyte's expertise in virus-like particle technology supports a pipeline of enhanced product candidates, including vaccines against norovirus, influenza and respiratory syncytial virus. LigoCyte has funded its product development efforts through a mix of private investment as well as grants and contracts administered through the National Institutes of Health and the U.S. Department of Defense, including a recent $3.6 million commitment from the agency. LigoCyte's investors include Forward Ventures, JAFCO, Novartis Venture Fund, Fidelity Biosciences, MedImmune Ventures, Athenian Venture Partners and MC Life Sciences Ventures (Mitsubishi International Corporation). The company closed its most recent financing in April 2010 from its existing venture investors. GlaxoSmithKline is also a shareholder of the company. For additional information on LigoCyte, please visit

The Phase I clinical studies were conducted with support from the U.S. Army Medical Research and Material Command under Contract No. W8IXWH-05-C-0135, from the University of Maryland General Clinical Research Center M00 RR 16500, GCRC Program, NCRR, NIH and from LigoCyte Pharmaceuticals, Inc.  The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. The investigator(s) adhered to the policies regarding the protection of human subjects as prescribed by 45 CFR 36 and 32 CFR 219 (Protection of Human Subjects).  Investigator(s) adhered to Guidelines for Research Involving Recombinant DNA Molecules; Notice, Federal Register, July 5, 1994, Volume 59, Number 127.

ChiSys® is a trade mark of Archimedes Development Ltd., and is registered as an EU Community Trademark, as a US Registered Trademark and in certain other jurisdictions.

SOURCE LigoCyte Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMedix Receives Clinical Approval for TRAKnet Software
2. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
3. Suzie Williams, CP Joins Orthocare Innovations as Clinical Services Manager
4. Kristalose(R) Clinical Data to Be Presented at Digestive Disease Week(R) Meeting
5. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
6. AFFiRiS AG: Alzheimers Vaccine AD02 Already in Clinical Phase II
7. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
8. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
9. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
10. Creating Healthcare Reform from the Inside Out Through Supply Chain Best Practices that Improve Financial and Clinical Performance is Focus of 2010 GHX Supply Chain Summit
11. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
Post Your Comments:
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):